Laboratory Corp (LH) Gets a Buy Rating from Morgan Stanley

In a report released today, Ricky Goldwasser from Morgan Stanley maintained a Buy rating on Laboratory Corp (LH), with a price target of $180. The company’s shares closed on Friday at $145.64, close to its 52-week low of $142.40.

According to, Goldwasser is a 3-star analyst with an average return of 3.0% and a 56.2% success rate. Goldwasser covers the Services sector, focusing on stocks such as Walgreens Boots Alliance, Quest Diagnostics Inc, and Charles River Labs.

Currently, the analyst consensus on Laboratory Corp is a Moderate Buy with an average price target of $170.50, representing a 17.1% upside. In a report issued on November 30, Piper Jaffray also maintained a Buy rating on the stock with a $177 price target.


See today’s analyst top recommended stocks >>

The company has a one-year high of $190.36 and a one-year low of $142.40. Currently, Laboratory Corp has an average volume of 824.1K.

Based on the recent corporate insider activity of 58 insiders, corporate insider sentiment is negative on the stock. Last month, Kerrii Anderson, a Director at LH sold 3,700 shares for a total of $604,136.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Laboratory Corp. of America Holdings is a clinical laboratory company, which engages in the provision of clinical laboratory and end-to-end drug development services. It operates through the LabCorp Diagnostics and Covance Drug Development segments. The LabCorp Diagnostics segment includes core testing as well as genomic and esoteric testing.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts